	US 12,453,756 B2
	GIP/GLP1 agonist compositions
Vincent John Corvari, Carmel, IN (US); Christopher Sears Minie, Zionsville, IN (US); Dinesh Shyamdeo Mishra, Carmel, IN (US); and Ken Kangyi Qian, Carmel, IN (US)
Assigned to ELI LILLY AND COMPANY, Indianapolis, IN (US)
Filed by Eli Lilly and Company, Indianapolis, IN (US)
Filed on Jan. 31, 2025, as Appl. No. 19/042,887.
Application 19/042,887 is a continuation of application No. 18/422,177, filed on Jan. 25, 2024.
Application 18/422,177 is a continuation of application No. 17/741,067, filed on May 10, 2022, granted, now 11,918,623, issued on Mar. 5, 2024.
Application 17/741,067 is a continuation of application No. 16/441,329, filed on Jun. 14, 2019, granted, now 11,357,820, issued on Jun. 14, 2022.
Claims priority of provisional application 62/688,632, filed on Jun. 22, 2018.
Prior Publication US 2025/0186544 A1, Jun. 12, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); A61K 9/00 (2006.01); A61K 38/16 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61M 5/20 (2006.01)

CPC A61K 38/16 (2013.01) [A61K 9/0019 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61M 5/20 (2013.01)]

14 Claims

1. A pharmaceutical composition comprising:

(a) tirzepatide, or a pharmaceutically acceptable salt thereof; and

(b) from about 6.2 mg/mL to about 9.5 mg/mL of NaCl,

wherein the pharmaceutical composition has a pH of from about 6.5 to about 7.5.